Sanoculis Achieves CE Mark Approval for MINT® Glaucoma Treatment Technology

Sanoculis' MINT®: A Groundbreaking Advancement in Glaucoma Treatment

Sanoculis Ltd., an innovative leader in the development of ophthalmic medical devices, has proudly announced the receipt of CE Mark approval for its pioneering product, MINT® (Minimally Invasive Nasal Trabeculostomy). This significant milestone allows Sanoculis to market this cutting-edge technology within the European Union, representing a major advancement in treatment options for patients suffering from glaucoma.

MINT® is designed to address glaucoma surgery's intricate challenges with a stent-free approach. This unique technology employs a semi-automated trephination process that creates 0.14 mm openings in the trabecular meshwork, which is essential for regulating intraocular pressure (IOP). Glaucoma affects millions globally, with projections estimating that the number of afflicted individuals may reach 112 million by 2040. Early detection and intervention are critical to preventing irreversible vision loss, as untreated glaucoma can lead to extensive optic nerve damage and degradation of visual fields.

Nir Israeli, Co-founder and CEO of Sanoculis, stated, "MINT® embodies a pivotal shift in Minimally Invasive Glaucoma Surgery (MIGS), with the potential to drastically enhance patient outcomes while elevating the overall standard of care in the field." The initial clinical studies for MINT® highlighted its safety and efficacy, showing significant reductions in intraocular pressure while minimizing the dependency on traditional glaucoma medications.

As part of its commitment to improving patient care, Sanoculis will initiate a selective commercial pre-launch of the MINT® technology later this year. This product represents not just a technical innovation but also a vital response to the increasing global challenge posed by glaucoma.

Understanding Glaucoma

Glaucoma is often referred to as the "silent thief of sight," owing to its insidious nature and the lack of early symptoms. It is a condition characterized by elevated intraocular pressure, which, if unmanaged, can lead to irreversible blindness. The moment pressure builds in the eye, damage to the optic nerve begins, eventually resulting in the loss of peripheral vision. Because of its chronic nature, managing glaucoma typically involves a multi-step treatment approach. It often begins with topical eye drops to reduce IOP, potentially advancing to laser therapy or MIGS.

Effective and timely intervention is paramount. The innovations brought forth by MINT® aim to provide a less invasive yet effective treatment for adults undergoing glaucoma angle surgery, ultimately protecting vision and improving quality of life for countless individuals.

The Future of Glaucoma Treatment

Sanoculis Ltd. has set an ambitious mission to lead in the development of advanced glaucoma treatment technologies. The proprietary solutions offered by the company promise to enhance the standard of care and improve outcomes in a field that is in constant need of innovative medical advancements. As the company continues to roll out the MINT® technology, it symbolizes a hopeful future for glaucoma patients looking towards minimally invasive options suitable for their needs.

For more information regarding MINT® and its upcoming commercial availability, interested parties can reach out to Sanoculis' global marketing team or visit their official website for comprehensive details.

Contact Information

For further inquiries, Elad Shalev, Vice President of Global Marketing and Sales, can be reached at +972509827282, or via email at shalev@sanoculis.com. To learn more about the MINT® technology, visit Sanoculis' YouTube page.